Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial

BACKGROUND: Dose modifications following adverse events (AEs) are an important part of the management of patients with pancreatic cancer treated with chemotherapy. While dose modifications are utilized to ensure patient safety, the subsequent influence of dose adjustments on treatment exposure and e...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Gastrointest Oncol
Main Authors: Scheithauer, Werner, Ramanathan, Ramesh K., Moore, Malcolm, Macarulla, Teresa, Goldstein, David, Hammel, Pascal, Kunzmann, Volker, Liu, Helen, McGovern, Desmond, Romano, Alfredo, Von Hoff, Daniel D.
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2016
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4880765/
https://ncbi.nlm.nih.gov/pubmed/27284481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.01.03
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki